Calcipotriol - MC2 Therapeutics

Drug Profile

Calcipotriol - MC2 Therapeutics

Alternative Names: Calcipotriene MC2-16 PAD™ Cream; MC2-01 (calcipotriol); MC2-04; MC2-16; PADcalci

Latest Information Update: 03 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Drug Delivery Solutions ApS
  • Developer Drug Delivery Solutions ApS; MC2 Therapeutics
  • Class Antipsoriatics; Cyclohexanes; Dihydroxycholecalciferols; Indenes; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Plaque psoriasis
  • Discontinued Psoriasis

Most Recent Events

  • 03 Apr 2017 Discontinued - Phase-II for Plaque psoriasis of MC2-01 calcipotriol in Germany (Topical, Ointment), because not listed on MC2 Therapeutics pipeline, April 2017
  • 03 Apr 2017 Preclinical trials of MC2-16 calcipotriol in Plaque psoriasis in Denmark (Topical, Cream) (MC2 Therapeutics pipeline, April 2017)
  • 29 Apr 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top